News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.
3 July 2023
Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study
22 June 2023
Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress
30 March 2023
Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer
8 March 2023
Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio Copy
23 January 2023
Events & Presentations
Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada
27 February 2020
ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA
4 September 2019
EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018
17 September 2018